RBM42

Across TCGA pan-cancer cohorts, RBM42 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RBM42 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher RBM42 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM42 expression acts as an unfavorable survival marker.

KICH, UCEC, and PCPG are the cancer types where RBM42 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
PCPG	DFS	Median	All	0.025	0.936	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RBM42–KICH (DFS)

Open the KICH breakdown →